ABIVAX Société Anonyme (0RA9.L)
| Previous close | 11.08 |
| Open | 11.34 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.18 - 11.34 |
| 52-week range | 5.68 - 19.58 |
| Volume | |
| Avg. volume | 5,413 |
| Market cap | 103.288M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings date | 09 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAbivax Provides Operational and Key Program Update
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire name
Globe NewswireAbivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Direct
